Ousia Labs’ patented subcritical extraction and flash chromatography systems bring precision, tunability, and flexibility to API manufacturers, formulators, and large-scale flavor and supplement processors. By mirroring industrial operating principles at a smaller scale, these systems empower commercial operators to improve quality, efficiency, and innovation across the production lifecycle.
Ousia Labs’ system re-circulates liquid CO₂ near the critical point (subcritical phase), where it has high density and low viscosity for efficient extraction. Operating at low temperature and moderate pressure preserves delicate compounds while allowing tunable selectivity for temperature and shear sensitive products. Continuous closed-loop recirculation improves yield, purity, and solvent efficiency with minimal energy use.
Ousia Labs’ patented extraction systems are engineered to continuously re-circulate liquid CO₂ through the extraction vessel in a closed-loop configuration. By maintaining precise control of temperature and pressure near the critical point—just below 1,071 psi and 88 °F—the CO₂ remains in a dense liquid (subcritical) phase rather than fully supercritical.
In this region, the solvent behaves like a hybrid between a gas and a liquid:
It has high density, giving it strong solvating power for essential oils, oleoresins, and other lipophilic compounds.
It retains low viscosity and surface tension, allowing it to penetrate plant material efficiently.
The subcritical conditions preserve CO₂ in a liquid-like state, which is easily condensed and re-used—forming a re-circulating solvent system that minimizes losses and energy demand.
The Ousia design maintains these conditions automatically through pressure regulation, thermal stabilization, and continuous CO₂ recovery, enabling repeatable operation with very small solvent volumes and rapid solvent turnover.
Click on a category below to learn more!
CO2 chromatography offers a dual advantage, utilizing a liquid to dissolve the medium matrix and an inert gas to propel materials through filters and media. Typically, the eluent strength is enhanced by incorporating a polar co-solvent, such as methanol, often with a low concentration (~1%) of a weak acid or base. While the solvent strength of CO2 can be heightened by increasing density or introducing a polar co-solvent, it’s crucial to note that this may result in the co-solvent dominating as the mobile phase. Common co-solvents include simple alcohols like methanol, ethanol, or isopropyl alcohol. For food-grade materials, it is advisable to opt for ethanol or ethyl acetate as co-solvents, both recognized as generally safe for food production.
Revolutionizing Active Pharmaceutical Ingredient (API) production through advanced CO₂ extraction, chromatography, and aseptic processing.
Traditional pharmaceutical extraction and purification technologies often rely on extreme pressures, hazardous solvents, and costly processing equipment, increasing production expenses and complicating regulatory compliance. Ousia Labs’ patented, closed-loop CO₂ extraction and chromatography systems offer a more efficient, scalable alternative designed to support high-purity API production while reducing operational costs.
Lower pressures mean lower costs without compromising quality. Many pharmaceutical compounds can be extracted, isolated, and purified under significantly milder conditions, reducing energy consumption, equipment requirements, and processing expenses while helping preserve sensitive molecular structures.
Our equipment is constructed from 100% 316 stainless steel, providing exceptional corrosion resistance, durability, and compatibility with pharmaceutical cleaning and sanitation protocols. Engineered with aseptic processing considerations, our systems are designed to minimize contamination risks, support closed-system operation, and facilitate integration into GMP-compliant manufacturing environments.
By combining precision CO₂ extraction, automated flash chromatography, and aseptic process engineering, Ousia Labs is advancing a new generation of pharmaceutical manufacturing technology—enabling more efficient API isolation, purification, and scalable production with fewer processing steps and reduced reliance on conventional organic solvents.
The result: Lower production costs, greater process control, and a scalable pathway to high-purity pharmaceutical ingredients.
Advanced CO₂ Extraction, Chromatography, and Isolator-Integrated Processing for Pharmaceutical Manufacturing
1. Safety – Engineered for Pharmaceutical and Aseptic Operations
Ousia Labs’ patented, closed-loop CO₂ extraction and chromatography systems provide a controlled approach to Active Pharmaceutical Ingredient (API) production, isolation, and purification. Utilizing CO₂ as the primary processing solvent reduces dependence on conventional organic solvents and their associated residual contamination risks. Our equipment features 100% 316 stainless steel construction, a corrosion-resistant material widely used in medical and pharmaceutical equipment for its durability, cleanability, and compatibility with appropriate sterilization methods. Integrated pressure-relief devices and controlled CO₂ circulation support operational safety. For applications requiring enhanced contamination control, Ousia Labs also offers custom integration of its systems within pharmaceutical isolators, providing an additional physical barrier between the processing environment and surrounding personnel and facilities. With appropriate engineering controls, validated sterilization procedures, and environmental monitoring, these configurations can support stringent aseptic manufacturing requirements.
2. Quality – High-Purity APIs and Contamination-Controlled Processing
Our technology combines precision-controlled CO₂ extraction with advanced flash chromatography to enable selective isolation and purification of pharmaceutical compounds. Constructed entirely from 316 stainless steel, our equipment is designed to facilitate cleaning, sanitation, and sterilization procedures essential to pharmaceutical manufacturing. Precise temperature and pressure control helps preserve sensitive molecular structures while supporting repeatable processing conditions. Optional isolator-integrated configurations further enhance contamination control by providing a dedicated, controlled processing environment that can be qualified for specific aseptic applications. This approach supports the development of reproducible manufacturing processes, rigorous quality assurance, and integration into GMP-regulated pharmaceutical production.
3. Efficiency – Automated, Scalable, and Aseptic-Ready
Ousia Labs advances pharmaceutical manufacturing through modular CO₂ extraction and automated chromatography technology designed to minimize manual intervention, reduce solvent consumption, and optimize production efficiency. Operating at lower pressures where appropriate for the target compound can reduce equipment demands and processing costs. Our automated column exchange technology enables extended processing sequences with fewer manual handling steps, creating opportunities to improve throughput and reduce contamination risks. By offering turnkey engineering and installation services for isolator-integrated systems, Ousia Labs provides pharmaceutical manufacturers with a configurable pathway from laboratory-scale API development to larger-scale, contamination-controlled production. Each installation can be engineered around the customer’s processing requirements, including appropriate cleaning, sterilization, environmental controls, and equipment qualification.
The Ousia Labs Advantage: Medical and pharmaceutical industry-compatible 316 stainless steel construction, precision CO₂ extraction, automated chromatography, and optional isolator integration—delivering a scalable platform engineered for high-purity API manufacturing and aseptic process applications.
